Haemonetics to Acquire Attune Medical

March 5, 2024

Haemonetics Corporation has entered into a definitive agreement to acquire privately held Attune Medical, the manufacturer of the ensoETM proactive esophageal cooling device used during RF cardiac ablation procedures. The deal calls for an upfront cash payment of $160 million at closing, plus additional contingent consideration tied to sales growth and other milestones, and is expected to close in Haemonetics’ fiscal first quarter of 2025.

Buyers
Haemonetics Corporation
Targets
Attune Medical
Location
United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.